Stock Market News

Regenxbio stock rises on FDA's priority review for MPS II therapy

May 13, 2025 - 13:52
 0
Regenxbio stock rises on FDA's priority review for MPS II therapy
Read More

Tags:

Previous Article

Boeing aims to integrate Saudi Arabia into F-15EX jet supply chain

Next Article

iTeos stock rises despite clinical trial setback

Related Posts

Teva Pharmaceutical's branded drugs boost first quarter profit

Teva Pharmaceutical's branded drugs boost first quarter...

May 7, 2025  0

US Department of Labor closes investigation into Scale AI

US Department of Labor closes investigation into Scale AI

May 9, 2025  0

CytomX Therapeutics shares soar on positive cancer drug data

CytomX Therapeutics shares soar on positive cancer drug...

May 12, 2025  0